| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HG57; CYSLT2; GPCR21; HPN321; CYSLT2R; KPG_011; hGPCR21; PSEC0146 |
| WB Predicted band size | 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human CYSLTR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CYSLTR2抗体的3篇参考文献示例(内容为虚构，仅供格式参考)：
---
1. **文献名称**：*Targeting CYSLTR2 with a monoclonal antibody inhibits angiogenesis in colorectal cancer*
**作者**：Zhang L, et al.
**摘要**：研究开发了一种靶向CYSLTR2的单克隆抗体，证明其通过阻断白三烯信号通路抑制结直肠癌血管生成，显著降低小鼠模型中肿瘤生长和转移。
---
2. **文献名称**：*CYSLTR2 overexpression correlates with poor prognosis in melanoma and is detectable by immunohistochemistry*
**作者**：Ramos M, et al.
**摘要**：利用CYSLTR2特异性抗体进行免疫组化分析，发现其在黑色素瘤中高表达，且与患者生存率降低相关，提示其作为预后生物标志物的潜力。
---
3. **文献名称**：*Anti-CYSLTR2 antibody attenuates airway inflammation in asthma models*
**作者**：Chen H, et al.
**摘要**：该研究通过抗体阻断CYSLTR2.显著减少哮喘小鼠模型的气道嗜酸性粒细胞浸润和炎症因子释放，表明白三烯受体靶向治疗的抗炎效果。
---
如需真实文献，建议通过PubMed或Google Scholar以“CYSLTR2 antibody”或“CYSLTR2 antagonist”为关键词检索。
The CYSLTR2 antibody targets the Cysteinyl Leukotriene Receptor 2 (CysLT2R), a G protein-coupled receptor (GPCR) that binds cysteinyl leukotrienes (CysLTs), such as LTE4. LTC4. and LTD4. These lipid mediators are critical in inflammatory and allergic responses, influencing processes like bronchoconstriction, vascular permeability, and immune cell recruitment. Unlike CysLT1R, which is well-characterized in asthma, CysLT2R has broader tissue expression, including vascular endothelium, smooth muscle, and the central nervous system, suggesting roles beyond classical inflammation, such as in cardiovascular diseases, fibrosis, and cancer.
CysLT2R activation triggers signaling pathways like Ca²⁺ mobilization, MAPK/ERK, and NF-κB, modulating cellular proliferation, apoptosis, and cytokine release. Its dual pro- and anti-inflammatory effects depend on cellular context. CYSLTR2 antibodies are vital tools for studying receptor localization, expression levels, and function in disease models. They enable immunohistochemical detection, Western blotting, and flow cytometry, aiding research on CysLT2R's role in pathologies like atherosclerosis, tumor angiogenesis, or neuroinflammation. Therapeutic potential is also explored, as aberrant CysLT2R signaling is linked to chronic inflammatory disorders and cancer progression. However, its complex biology necessitates further research to clarify mechanistic nuances and validate clinical applications.
×
